Compare SQNS & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SQNS | RVPH |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.3M | 71.0M |
| IPO Year | 2011 | N/A |
| Metric | SQNS | RVPH |
|---|---|---|
| Price | $4.89 | $0.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $21.33 | $3.33 |
| AVG Volume (30 Days) | 155.3K | ★ 8.4M |
| Earning Date | 02-10-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,534,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.20 | N/A |
| 52 Week Low | $4.44 | $0.25 |
| 52 Week High | $58.30 | $2.17 |
| Indicator | SQNS | RVPH |
|---|---|---|
| Relative Strength Index (RSI) | 40.69 | 30.55 |
| Support Level | $4.44 | $0.27 |
| Resistance Level | $4.88 | $0.34 |
| Average True Range (ATR) | 0.35 | 0.06 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 23.41 | 9.85 |
Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its offer 5G/4G chips and modules fully optimized for non-smartphone devices. The company covers applications such as smart mobility and logistics, smart utility meters, smart cities, smart industries, e-health and wellness, and smart homes to name few. The Company has one operating segment, which is the design and marketing of semiconductor components for cellular wireless systems. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.